MaaT Pharma To Release First in Patients Data At The 2017 ASH Meeting On Autologous Fecal Microbiota Transfer And Restoration Of Microbiota Diversity

The French Microbiome company completed its first clinical study proving that Autologous Fecal Microbiota Transfer induced a 90% recovery of gut microbiome diversity. These promising results could open new avenues for treating several conditions in the hematology-oncology field.

November 30, 2017
MaaT Pharma

(Lyon-France) – November 30, 2017 – MaaT Pharma, a French-based microbiome company developing innovative treatments for unmet medical needs in hematology-oncology, infection diseases and immune diseases such as GvHD, announces that data related to MaaT011* will be the subject of one poster presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exhibition on December 9-12 in Atlanta, USA.

PR available here